# Cytek Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cytek-biosciences

- Industry: Medical Devices & Equipment
- Headquarters: Fremont, US
- Website: www.cytekbio.com
- Total disclosed funding: $190M
- Latest round: Series D (Oct 22, 2020)
- Investors on record: 9

## About

Based in California, US, and founded in 1992, Cytek Biosciences, Inc., formerly known as Cytoville, it operates as a manufacturer and supplier of flow cytometry instruments for researchers and clinicians. The company was co-founded by Ming Yan and Wenbin Jiang and is backed by Series D funding from Hillhouse Capital Group, Lyfe Capital, OrbiMed Advisors, and RA Capital in November 2020. In July 2021, the firm became a public company under the ticker symbol CTKB on the Nasdaq.

The company's products include Cytek Aurora, Cytek Aurora CS (Cell-Sorter), Cytek Northern Lights, and Northern Lights-CLC, which deliver high-resolution cell analysis through the use of the full spectrum of fluorescence signatures from multiple lasers. Cytek Biosciences offers services such as cytometry training and cytometer validation. The company also provides an e-commerce platform that allows customers to buy reagents, beads, filters, cap assembly, cFluor anti-human, and dye kits.

The company generated a revenue of USD 92.84 million for 2020 and USD USD 57.9 million in 2019.

## Funding rounds

- Series D, Oct 22, 2020, $120M — OrbiMed Advisors, Hillhouse Investment, RA Capital Management, LYFE Capital
- Series C, Sep 24, 2018, $58M — NLVC, 3E Bioventures Capital
- Series A, Jun 1, 2015, $12M — Eight Roads Ventures, F-Prime Capital, Easy Prosperity

## Investors

- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- Easy Prosperity — Series A
- NLVC (https://capitalatlas.ai/funds/nlvc) — Series C
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series D
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series D
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series D
- LYFE Capital — Series D